Pain: GPCR and Nerve Growth Factor-Based Therapies Offer Strong Potential in Difficult-to-Treat Subtypes

2019-04-17
Price :
Published : Apr-2019
No. of Pages : 75

Pain: GPCR and Nerve Growth Factor-Based Therapies Offer Strong Potential in Difficult-to-Treat Subtypes

Summary

The pain therapeutics market has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established active pharmaceutical ingredients and mechanisms of action. The moderate-to-severe pain space continues to be dominated by opioids, which are increasingly being reformulated to offer abuse resistance, whereas mild pain is effectively treated with non-steroidal anti-inflammatory drugs (NSAIDs). However, significant unmet needs remain, as chronic pain subtypes-particularly neuropathic pain-do not respond well to existing therapies. This report assesses first-in-class innovation across the pain pipeline.

Scope

– There are 909 pipeline programs in active development for pain. What proportion of these products are first-in-class? How does first-in-class innovation vary by development stage and molecular target class?
– The market for pain treatment is heavily saturated. Which drug classes are used to treat pain? How do the drug classes in the market compare with those in the pipelines?
– Which molecular target classes are prominently represented in the first-in-class pain pipelines? Which first-in-class targets have been identified as most promising for the treatment of pain? Which first-in-class products have prior deal involvement?

Reasons to buy

– Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems and epidemiology for major pain subtypes.
– Visualize the composition of the pain market in terms of dominant molecule types and molecular targets. This knowledge allows a competitive understanding of gaps in the current market.
– Analyze and compare the pain pipeline and stratify by stage of development, molecule type, and molecular target.
– Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
– Recognize commercial opportunities by identifying first-in-class pipeline products for pain that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for first-in-class pain products.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Ambulatory Surgical Centers Market by Product (EHR, Practice Management, Telehealth, Healthcare Analytics, PHM, Supply Chain Management, RCM, Surgical planning, Quality Management), Specialty Type (Single, Multi-specialty) – Global Forecast to 2025

The Ambulatory Surgical Centers market is projected to reach USD 7.2 billion by 2025 from 2.1 billion in 2020 at a CAGR of 27.6% during the forecast period.There is a growing inclination across the globe towards the adoption of healthcare IT technologies due to the increasing need to deliver quality care to patients while curtailing escalating healthcare costs. These robust IT solutions are designed to streamline workflow in healthcare systems, reduce expenses, and facilitate compliance with stringent regulatory guidelines. By-products and services, the healthcare providers segment accounted for the largest share of the Ambulatory Surgical Centers market in 2018 Based on products and services, the Ambulatory Surgical Centers market is segmented into healthcare provider solutions, h......
$5650

Risk-based Monitoring Software Market by End User (Pharma & Biopharmaceutical Co., Medical Device Co., CROs), Delivery Mode (Web Hosted, On-premise, Cloud-based), Type (Enterprise, Site), Component (Software, Services) – Global Forecast to 2025

“Risk-based monitoring (RBM) software market is projected to grow at a CAGR of 13.3%.” The RBM software market is expected to reach USD 511 million by 2025 from USD 273 million in 2020, at a CAGR of 13.3% during the forecast period. The RBM software market has witnessed various advancements in products and their approvals to meet the needs of the pharmaceutical research and development industry worldwide. Growth in the market can primarily be attributed to factors such as the cost and time efficiency of RBM solutions, rising number of clinical trials, and increasing government funding and grants to support clinical trials “The Enterprise RBM Software segment to hold the largest market share in 2020.” Based on type, the RBM software market is segmented into Enterprise RB......
$5650

Veterinary Vaccines Market by Disease (Swine Pneumonia, Avian Influenza, Rabies, Coccidiosis, Brucellosis, Canine Distemper), Type (Poultry, Livestock, Aquaculture, Porcine, Canine), Technology (Inactivated, Toxoid, Recombinant) – Global Forecast to 2025

“The veterinary vaccines market is projected to grow at a CAGR of 7.2% during the forecast period (2020–2025).” The global veterinary vaccines market size is projected to reach USD 11.3 billion by 2025 from USD 8.0 billion in 2020, at a CAGR of 7.2%. The growth of this market is driven majorly by factors such as the initiatives by various government agencies and animal associations to maintain animal health, rising incidence of zoonotic diseases, growth in the companion animal population, and the rising demand for animal-derived food products are driving the growth of this market. On the other hand, the high storage cost of vaccines is restraining market growth. “By technology, the recombinant vaccines segment is expected to grow at the highest CAGR during the forecast period......
$4950

COVID-19 Impact on Vaccines & Drugs Market – Global Forecast to 2025

"The global COVID 19 vaccines market is projected to grow at a CAGR of -14.9% during the forecast period." The global COVID-19 vaccines market is projected to reach USD 1,401 million by 2025 from USD 2,273 million in 2022, at a CAGR of -14.9% during the forecast period. The growth of the global COVID-19 vaccines market is majorly attributed to the increasing number of people infected with COVID-19 and growing funding for vaccine development. "The global COVID 19 drugs market is projected to grow at a CAGR of -57.8% during the forecast period." The global COVID-19 drugs market is projected to reach USD 2 million by 2025 from USD 165 million in 2020, at a CAGR of -57.8% during the forecast period. The growth of COVID-19 drugs market is attributed primarily to use of repurposed drugs......
$5650

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides ......
$1000

Pharmaceutical Trade and Supply Chain Survey – Q1 2020: Coronavirus Disease 2019 (COVID-19) Sector Impact

Pharmaceutical Trade and Supply Chain Survey - Q1 2020: Coronavirus Disease 2019 (COVID-19) Sector Impact Summary GlobalData's Coronavirus Disease 2019 (COVID-19) Sector Impact: Pharmaceutical Trade and Supply Chain Survey - Q1 2020 provides in-house analyst expertise on the results of a 5 minute survey of 136 GlobalData Pharma clients and prospects, which was fielded from March 13, 2020 to March 24, 2020. Scope - This report provides an assessment of how the pharmaceutical industry perceives the supply chain disruption caused by the COVID-19 pandemic, including the challenges associated with clinical trials, logistics, API and finished dose manufacturing. - Since the first case was diagnosed in Wuhan, China, in December 2019, COVID-19 cases have continued to rise rapidly across the gl......
$1495

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Russia

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Russia Summary GlobalData, the industry analysis specialist, has released its latest report: "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Russia". The report is an essential source of information on analysis of the healthcare, regulatory and reimbursement landscape in Russia. It identifies the key trends in the country's healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets. It uses data and information sourced from proprietary databases, secondary research, and in-house analysis by Glo......
$1995

Social Media: Coronavirus Disease (COVID-19) Sector Impact

Social Media: Coronavirus Disease (COVID-19) Sector Impact Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. This report analyzes GlobalData's social media Influencer dashboards to understand Influencer trends since the pandemic began and what key Influencers are discussing online about COVID-19. across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. Scope - This report analyzes Influencer trends since the pandemic began and what assesses what key Influencers are discussi......
$995

Biopharmaceutical Venture Capital Trends: Coronavirus Disease (COVID-19) Company Impact Report

Biopharmaceutical Venture Capital Trends: Coronavirus Disease (COVID-19) Company Impact Report Summary This report examines the impact of the COVID-19 pandemic on venture capital deals for biopharmaceutical companies. This analysis is critical to understanding how the outbreak of COVID-19 impacted investments and how those VC deal trends may impact current and future venture capital investments. Scope This report is required reading for - - Investors that want to understand how COVID-19 has impacted VC deals in the biopharmaceutical industry as well as identifying companies that may be due for a round of financing in upcoming months - Companies that are due to raise venture capital in the near future and need to consider 2020 VC trends into their capital raising strategies. - Large ph......
$695

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Poland

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Poland Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Poland". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in the Poland. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of the Poland. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house ......
$1995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy